Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Cantor Fitzgerald Reiterates Overweight Rating on Repay (RPAY) Following APS Acquisition
-
Reata Pharmaceuticals (RETA) PT Raised to $180 at Cantor Fitzgerald on Favorable MOXIe Data
-
Cantor Fitzgerald Starts Exagen (XGN) at Overweight
-
Makor Securities London Ltd Receive Regulatory (FCA) Approval to Operate an Organized Trading Facility ('OTF'), Providing Service Continuity to All Clients Across Products, Venues and Execution Protoc
-
Cantor Fitzgerald Upgrades GlaxoSmithKline (GSK:LN) (GSK) to Buy
-
Freddie Mac Prices $489 Million Multifamily KG-Deal, K-G02
-
Cantor Fitzgerald Starts Endava PLC (ADR) (DAVA) at Neutral
-
Positive 12-Month Data a Major De-Risking Event for ProQR Therapeutics N.V. (PRQR) QR-110 - Cantor Fitzgerald
-
Mission Rock Residential Assumes Management of Nashville Apartments
-
Hamilton Zanze Acquires Rivertop Apartments in Nashville
-
Cantor Fitzgerald Reiterates Overweight Rating on Global Blood Therapeutics (GBT) Following Analyst Day
-
Institute for Portfolio Alternatives Elects New Board Members for 2020
-
UPDATE: Mereo BioPharma (MREO) Receives FDA Fast Track Designation for Navicixizumab for Treatment of Heavily Pretreated Ovarian Cancer
-
Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer
-
Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer
-
Nevakar Enters into $17.5 Million Product Financing Agreement with H.I.G. Capital Partners for Continued Development of Injectable Products
-
Regulators fine New York's BGC Partners $25 million for forex options fraud
-
R.W. Pressprich Continues to Build Fixed Income Credit Team
-
Kindred Biosciences Secures $50 Million Debt Facility with Solar Capital Partners
-
Fennec to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019
-
Cellular Biomedicine Group to Present at the 2019 Cantor Global Healthcare Conference
-
Heron Therapeutics (HRTX) HRX-011 Resubmission a 'Significant Positive' - Cantor Fitzgerald
-
Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
-
Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
-
Refuge Biotechnologies to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
-
Amicus Therapeutics to Present at Upcoming Medical and Investor Conferences in October 2019
-
Cantor Fitzgerald Reiterates Overweight Rating on Geron Corporation (GERN)
-
Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences
-
Theratechnologies to Present at Cantor Fitzgerald Global Healthcare Conference in New York City
-
Theratechnologies to Present at Cantor Fitzgerald Global Healthcare Conference in New York City
-
Amgen's (AMGN) ESMO Data Highlights AMG-510 as a Top Pipeline Program - Cantor Fitzgerald
-
BiomX to Present at the Cantor Fitzgerald Global Healthcare Conference
-
Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
-
Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
-
R1 RCM to Present at the Cantor Fitzgerald 2019 Global Healthcare Conference
-
Merck to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
-
Iterum Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
-
Iterum Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
-
Adamas to Present at Upcoming Cantor Fitzgerald Investor Conference
-
Genocea Biosciences (GNCA) Announces Poster Presentation at ESMO
-
Vericel to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019
-
Genocea Announces Poster Presentation at The European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona and Presentation at an Upcoming Investor Conference
-
Genocea Announces Poster Presentation at The European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona and Presentation at an Upcoming Investor Conference
-
Vericel to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019
-
Trevena to Present at the 2019 Cantor Global Healthcare Conference
-
Tmunity Announces Presentation at the Cantor Fitzgerald 2019 Global Healthcare Conference
-
AnaptysBio to Present at the Cantor Fitzgerald Global Healthcare Conference
-
AnaptysBio to Present at the Cantor Fitzgerald Global Healthcare Conference
-
Cantor Fitzgerald Starts Stealth BioTherapeutics (MITO) at Overweight
-
Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

